Monograph

MAFEnzalutamide Capsule 40 mg

1) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
2) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic hormone-sensitive prostate cancer (mHSPC).
3) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic castration-resistant prostate cancer (mCRPC).

MSHLEnzalutamide Capsule 40 mg

1) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
2) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic castration-resistant prostate cancer (mCRPC).
3) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic hormone-sensitive prostate cancer (mHSPC).